SHR-A1811 for HER2-positive Breast Cancer Neoadjuvant Therapy

This clinical trial focuses on comparing two different treatment methods for people with early-stage or locally advanced HER2-positive breast cancer. The study involves 650 participants who are randomly divided into two groups. One group receives a new treatment called SHR-A1811, while the other group receives a combination of drugs known as TCbHP, which includes Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. This research aims to discover which treatment is more effective at shrinking tumors before surgery, potentially leading to better long-term outcomes for patients fighting this type of breast cancer. Participants in the study will receive their assigned treatment as a "neoadjuvant" therapy, meaning it is given before surgery to help reduce the tumor size. Those receiving SHR-A1811 will have it as a standalone treatment, while the others will receive the TCbHP combination. After completing this phase, participants will undergo surgery to remove any remaining cancer. The effectiveness of these treatments will be assessed through a detailed examination of the removed tissue. The study measures success by the rate of "tpCR," which means no invasive cancer is found in the breast tissue or lymph nodes after surgery. Participants will be monitored for at least three years to track their recovery and check for any recurrence of cancer, ensuring a comprehensive evaluation of the treatments' long-term benefits and risks.